171 related articles for article (PubMed ID: 18220520)
21. Targeted etanercept for treatment-refractory pain due to bone metastasis: two case reports.
Tobinick EL
Clin Ther; 2003 Aug; 25(8):2279-88. PubMed ID: 14512134
[TBL] [Abstract][Full Text] [Related]
22. Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.
van Herwaarden N; den Broeder AA; Jacobs W; van der Maas A; Bijlsma JW; van Vollenhoven RF; van den Bemt BJ
Cochrane Database Syst Rev; 2014 Sep; (9):CD010455. PubMed ID: 25264908
[TBL] [Abstract][Full Text] [Related]
23. Systemic and spinal administration of etanercept, a tumor necrosis factor alpha inhibitor, blocks tactile allodynia in diabetic mice.
Dogrul A; Gul H; Yesilyurt O; Ulas UH; Yildiz O
Acta Diabetol; 2011 Jun; 48(2):135-42. PubMed ID: 21104419
[TBL] [Abstract][Full Text] [Related]
24. Targeted etanercept for discogenic neck pain: uncontrolled, open-label results in two adults.
Tobinick EL
Clin Ther; 2003 Apr; 25(4):1211-8. PubMed ID: 12809967
[TBL] [Abstract][Full Text] [Related]
25. Perispinal Delivery of CNS Drugs.
Tobinick EL
CNS Drugs; 2016 Jun; 30(6):469-80. PubMed ID: 27120182
[TBL] [Abstract][Full Text] [Related]
26. Phase I/II parallel double-blind randomized controlled clinical trial of perispinal etanercept for chronic stroke: improved mobility and pain alleviation.
Ralph SJ; Weissenberger A; Bonev V; King LD; Bonham MD; Ferguson S; Smith AD; Goodman-Jones AA; Espinet AJ
Expert Opin Investig Drugs; 2020 Mar; 29(3):311-326. PubMed ID: 31899977
[No Abstract] [Full Text] [Related]
27. A double-blind, placebo-controlled, dose-response pilot study evaluating intradiscal etanercept in patients with chronic discogenic low back pain or lumbosacral radiculopathy.
Cohen SP; Wenzell D; Hurley RW; Kurihara C; Buckenmaier CC; Griffith S; Larkin TM; Dahl E; Morlando BJ
Anesthesiology; 2007 Jul; 107(1):99-105. PubMed ID: 17585221
[TBL] [Abstract][Full Text] [Related]
28. [Etanercept. An effective TNF alpha-antagonist in the treatment of psoriatic arthritis and chronic plaque psoriasis].
Wozel G
Hautarzt; 2005 Sep; 56(9):819-30. PubMed ID: 16133634
[TBL] [Abstract][Full Text] [Related]
29. Combining etanercept and acitretin in the therapy of chronic plaque psoriasis: a 24-week, randomized, controlled, investigator-blinded pilot trial.
Gisondi P; Del Giglio M; Cotena C; Girolomoni G
Br J Dermatol; 2008 Jun; 158(6):1345-9. PubMed ID: 18410408
[TBL] [Abstract][Full Text] [Related]
30. Comparison of clinical and pharmacokinetic profiles of etanercept 25 mg twice weekly and 50 mg once weekly in patients with psoriasis.
Elewski B; Leonardi C; Gottlieb AB; Strober BE; Simiens MA; Dunn M; Jahreis A
Br J Dermatol; 2007 Jan; 156(1):138-42. PubMed ID: 17199580
[TBL] [Abstract][Full Text] [Related]
31. Tumor necrosis alpha-blocking agent (etanercept): a triple blind randomized controlled trial of its use in treatment of sciatica.
Okoro T; Tafazal SI; Longworth S; Sell PJ
J Spinal Disord Tech; 2010 Feb; 23(1):74-7. PubMed ID: 20072036
[TBL] [Abstract][Full Text] [Related]
32. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.
Moreland LW; Schiff MH; Baumgartner SW; Tindall EA; Fleischmann RM; Bulpitt KJ; Weaver AL; Keystone EC; Furst DE; Mease PJ; Ruderman EM; Horwitz DA; Arkfeld DG; Garrison L; Burge DJ; Blosch CM; Lange ML; McDonnell ND; Weinblatt ME
Ann Intern Med; 1999 Mar; 130(6):478-86. PubMed ID: 10075615
[TBL] [Abstract][Full Text] [Related]
33. Treatment of post-anesthesia dementia with perispinal etanercept injection and hyperbaric oxygen therapy: a case report.
Best S; Pavel DG
J Med Case Rep; 2017 Apr; 11(1):105. PubMed ID: 28407792
[TBL] [Abstract][Full Text] [Related]
34. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis.
Tyring S; Gordon KB; Poulin Y; Langley RG; Gottlieb AB; Dunn M; Jahreis A
Arch Dermatol; 2007 Jun; 143(6):719-26. PubMed ID: 17576937
[TBL] [Abstract][Full Text] [Related]
35. Etanercept, a soluble tumor necrosis factor receptor, palliates constitutional symptoms in patients with myelofibrosis with myeloid metaplasia: results of a pilot study.
Steensma DP; Mesa RA; Li CY; Gray L; Tefferi A
Blood; 2002 Mar; 99(6):2252-4. PubMed ID: 11877307
[TBL] [Abstract][Full Text] [Related]
36. Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly.
Braun J; McHugh N; Singh A; Wajdula JS; Sato R
Rheumatology (Oxford); 2007 Jun; 46(6):999-1004. PubMed ID: 17389658
[TBL] [Abstract][Full Text] [Related]
37. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor alpha receptor fusion protein etanercept.
Baraliakos X; Davis J; Tsuji W; Braun J
Arthritis Rheum; 2005 Apr; 52(4):1216-23. PubMed ID: 15818694
[TBL] [Abstract][Full Text] [Related]
38. NLRP3-dependent synaptic plasticity deficit in an Alzheimer's disease amyloidosis model in vivo.
Qi Y; Klyubin I; Cuello AC; Rowan MJ
Neurobiol Dis; 2018 Jun; 114():24-30. PubMed ID: 29477641
[TBL] [Abstract][Full Text] [Related]
39. A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis.
Boetticher NC; Peine CJ; Kwo P; Abrams GA; Patel T; Aqel B; Boardman L; Gores GJ; Harmsen WS; McClain CJ; Kamath PS; Shah VH
Gastroenterology; 2008 Dec; 135(6):1953-60. PubMed ID: 18848937
[TBL] [Abstract][Full Text] [Related]
40. Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension.
van de Kerkhof PC; Segaert S; Lahfa M; Luger TA; Karolyi Z; Kaszuba A; Leigheb G; Camacho FM; Forsea D; Zang C; Boussuge MP; Paolozzi L; Wajdula J
Br J Dermatol; 2008 Nov; 159(5):1177-85. PubMed ID: 18673365
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
